Literature DB >> 11909765

A comparative study of genotoxic effects of anti-topoisomerase II drugs ICRF-193 and bufalin in Chinese hamster ovary cells.

Nuria Pastor1, Inmaculada Domínguez, Santiago Mateos, Felipe Cortés.   

Abstract

With the ultimate purpose of testing the existence of possible differences in the effectiveness of the topoisomerase II catalytic inhibitor ICRF-193 (a bisdioxopiperazine) and the enzyme suppressor bufalin (a bufadienolide from toad venom) we have carried out a series of experiments aimed at inducing cytotoxicity as well as DNA and chromosome damage in transformed CHO cells. In order to assess any possible influence of DNA repair capacity of the treated cells on the final outcome, we have made use of the repair-defective CHO mutant EM9, which shows a defect in DNA single- and double-strand breaks repair for comparison with its repair-proficient parental line AA8. Our results seem to indicate that, while both ICRF-193 and bufalin suppress cell growth and result in a clear inhibition of topoisomerase II catalytic activity, only ICRF-193 has been shown as able to induce both chromosome and DNA damage, with a more pronounced effect in the CHO mutant EM9 than in the repair-proficient line AA8.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11909765     DOI: 10.1016/s1383-5718(02)00011-6

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  2 in total

1.  An experimental study on the anti-Ehrlich ascites carcinoma effect of purified toad venom extract.

Authors:  Ying Wang
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-10-03

2.  Triggering apoptotic death of human malignant melanoma a375.s2 cells by bufalin: involvement of caspase cascade-dependent and independent mitochondrial signaling pathways.

Authors:  Yu-Ping Hsiao; Chun-Shu Yu; Chien-Chih Yu; Jai-Sing Yang; Jo-Hua Chiang; Chi-Cheng Lu; Hui-Ying Huang; Nou-Ying Tang; Jen-Hung Yang; An-Cheng Huang; Jing-Gung Chung
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-07       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.